Non-Muscle Invasive Bladder Cancer: AUA/SUO Treatment Algorithm



*Consider fulguration in low-volume disease recurrence; otherwise reassess as intermediate risk.

†Timely re-TURBT (within six weeks) should be performed if there are concerns regarding an incomplete resection and/or if bladder sparing treatment (e.g., intravesical therapy or surveillance), is being planned.

©2020 American Urological Association

Bladder Cancer: Non-Muscle Invasive